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1. Objective 
The South African Thoracic Society, in conjunction with 
interested stakeholders, published a Guideline for Influenza 
Management in Adults in 1999.1  This year the South African 
Thoracic Society (SATS) identified the need to revise that 
guideline for the following reasons:
•    To indicate the viral strains that are to be incorporated into 
the vaccine for the 2008 season
•    To add important new data regarding treatment of influenza
•    To add a section on influenza in children
•    To clarify issues in managing and preventing influenza in 
HIV-infected individuals.  
2. Influenza – the virus
2.1 Structure 
Influenza virus is a middle-sized virus about 80 - 120 nm in 
diameter.  Like all viruses it consists of a genome covered 
by protein shell (capsid) and, being an enveloped virus, by a 
surrounding bilipid layer derived from the cellular cytoplasmic 
membrane as the virus buds out of the host cell at the end of its 
replication cycle.  Because of the loose envelope, the shape of the 
virus is pleomorphic, varying from spherical to tubular.
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Objective. The South African Thoracic Society, in conjunction 
with interested stakeholders, published a Guideline for 
Influenza Management in Adults in 1999. This year the South 
African Thoracic Society (SATS) identified the need to revise 
that guideline for the following reasons:
•    To indicate the viral strains that are to be incorporated into 
the vaccine for the 2008 season
•    To add important new data regarding treatment of 
influenza
•    To add a section on influenza in children
•    To clarify issues in managing and preventing influenza in 
HIV-infected individuals.  
Influenza virus. The influenza virus genus belongs to the 
family orthomyxoviridae. The haemagglutinin (HA) protein 
is the outermost protein, responsible for attachment to the 
host receptor, and is critical in determining the host’s immune 
response to the virus.  Changes in the antigenic epitopes of 
HA therefore allow the virus to escape the host’s specific 
immune response. The genus is classified into three types, 
A, B and C, on the basis of the antigenic epitopes of the 
nucleoprotein (NP). Type A, which is widespread in nature in 
birds and mammals, is the most important type clinically and 
epidemiologically.  It is further divided into subtypes on the 
basis of the antigenic epitopes of the HA and neuraminidase 
(NA) proteins.  Each of the human subtypes H1N1, H2N2 and 
H3N2 are further subdivided into strains on the basis of more 
subtle antigenic properties of the HA protein.
Influenza vaccination. Influenza vaccine is the mainstay of 
influenza prevention strategies. All persons who are at high 
risk of influenza and its complications because of underlying 
medical conditions or who are receiving regular medical care 
for conditions such as chronic pulmonary and cardiac disease, 
chronic renal diseases, neuromuscular diseases, diabetes 
mellitus and similar metabolic disorders, and individuals 
who are immunosuppressed (including HIV-infected persons 
with CD4 counts above 100 cells/µl and HIV-infected children 
with CD4 counts >15%), should be vaccinated. Vaccines 
should be given from at least 2 months prior to the onset of 
autumn (March in South Africa). The recommended vaccine 
formulation for 2008 is:
•    A/Solomon Islands/3/2006 (H1N1) (IVR-145)
•    A/Brisbane/10/2007 (H3N2) (IVR-147)
•    B/Florida/4/2006 or B/Brisbane/3/2007.
Treatment of influenza. Influenza illness is characterised by 
the acute onset of systemic and respiratory signs occurring 
in autumn or winter. Recommendations for the Prevention 
and Control of Influenza have indicated that neither 
amantadine nor rimantadine should be used for the treatment 
or chemoprophylaxis of influenza A. NA inhibitors are 
an important adjunct to influenza vaccination, in both the 
prevention and treatment of influenza. Because of concerns 
about the possibility of the development of viral resistance 
with overuse of these agents, it is recommended that NA 
inhibitors in the treatment of influenza should be reserved for 
high-risk or sicker influenza patients. 
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The genome consists of a single-stranded RNA of negative 
polarity (i.e. the viral RNA or vRNA is not translated 
directly into protein but via an intermediate mirror-image 
complementary RNA or cRNA strand), so that vRNA 
transcribes to cRNA which then translates to protein.  
Replication of the RNA is mediated by a viral enzyme, RNA-
dependent RNA polymerase, also known as RNA replicase. 
Covering the genome, and closely attached to it, is the 
nucleoprotein (NP) which is in turn covered by the matrix 
protein (M), the major protein bulk of the virus.  The matrix 
gene codes for two matrix proteins, M1, which is the major 
component of the capsid, and M2, a protein embedded in the 
envelope of the virus, which forms an ion exchange channel 
that facilitates the penetration of the virus into the host cell.  In 
addition there are two non-structural viral proteins, NS1 and 
NS2.
A lipid bilayer is acquired by the virus from the host cell 
cytoplasmic membrane as it buds out of the host cell to infect 
new cells after its replication.  Embedded in this envelope 
are the two viral spikes, also referred to as peplomers, 
haemagglutinin (H or HA) and neuraminidase (N or NA).
HA is a rod-shaped trimeric protein.  Each monomer 
comprises two segments, a proximal HA2 component which is 
embedded in the viral envelope, and a distal HA1 component 
which attaches to (sialic) neuraminic acid receptor of the host. 
The cleavage site between HA1 and HA2 consists of a short 
oligopeptide sequence called the fusion peptide.  In the highly 
pathogenic forms of avian influenza (HPAI) this cleavage 
site consists of basic amino acids; this is used as a diagnostic 
marker of HPAI. The HA protein also attaches to red blood 
cells causing them to clump together, i.e. haemagglutination; 
this forms the basis of a commonly used serological test for the 
virus, the haemagglutination test, or for antibodies to the virus, 
the haemagglutination inhibition test.
The other surface spike protein, NA, is a mushroom-
shaped protein with its stalk embedded in the virus envelope.  
Being an enzyme, NA’s function is to digest the cell surface 
neuraminic acid to free the virus from the cell after its 
replication cycle and allow it to infect further cells.
The HA protein, being the outermost protein and responsible 
for attachment to the host receptor, is critical in determining 
the host’s immune response to the virus.  Changes in antigenic 
epitopes of HA allow new viral infections to escape pre-
existing humoral responses induced by non-matching strains of 
influenza virus.  To a lesser extent, the immune response to NA 
is also responsible for protection and also for recovery from 
infection.
2.2 Classification
The influenza virus genus belongs to the family 
orthomyxoviridae.  The genus is classified into three types, 
A, B and C, on the basis of the antigenic epitopes of the NP 
protein.  Type A, which is widespread in nature in birds 
and mammals, is the most important type clinically and 
epidemiologically.  It is further divided into subtypes on 
the basis of the antigen sequence diversity of the HA and 
NA proteins.  In nature some 16 HAs and 9 NAs have been 
described, all of which are found in birds, while relatively few 
have been detected in mammals.  In man only H1, H2 and H3 
and N1 and N2 in the combinations H1N1, H2N2 and H3N2 
have so far been associated with regular outbreaks of human 
influenza.  Only on rare occasions have the non-human viruses 
crossed the species barrier from birds to infect humans, but 
these have only caused sporadic cases of influenza and have 
not established themselves in the human host to the extent of 
being transmissible between humans.
Types B and C influenza virus are found exclusively in 
humans.  They are not classified into subtypes, but each type 
is subdivided into strains. Type C is mainly a cause of minor 
upper respiratory tract infection and is therefore not included 
in the vaccine. 
The nomenclature for influenza strains details, in sequence, 
the type, subtype (in the case of type A) and the strain 
identifiers – the place where it was first characterised, the 
year of isolation and a laboratory identifying number.  The 
following strains that have been identified by the World Health 
Organization for the 2008 Southern Hemisphere influenza 
season are set out in Table I.2  
3. Influenza vaccine strategy
Influenza vaccine forms the most important basis for 
prevention of influenza disease. Vaccines should contain 15 µg 
of each HA antigen in each 0.5 ml dose. Tables II and III list 
the indications for influenza vaccine in adults and children, 
respectively. Table IV lists the influenza vaccine dosages and 
Table V the contraindications to vaccination. Vaccination 
should be given sufficiently early to provide protection for the 
autumn and winter. A protective antibody response takes about 
2 weeks to develop. However, vaccination can and should be 
done at any time of the season, even until late winter.
4. Clinical disease in adults 
Influenza occurs in autumn and winter in South Africa. Cases 
are reported from April to October. A clinical diagnosis of 
influenza is usually sufficient. In adults sudden onset of fever 
and cough during the influenza season has been reported to have a 
positive predictive value of 79%.3 The main underlying disorders 
associated with increased risk of complications from influenza 
are chronic respiratory and cardiac conditions (Table VI). 
Table I. Viral strains for 2008
•    A/Solomon Islands/3/2006 (H1N1)-like virus
•    A/Brisbane/10/2007 (H3N2)-like virus
•    B/Florida/4/2006-like virus or B/Brisbane/3/2007
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5. Clinical disease in children 
Influenza illness is characterised by the acute onset of systemic 
and respiratory signs.3,4 The abrupt onset and systemic signs in 
a child during the influenza season should enable influenza to 
be distinguished from a simple upper respiratory tract infection 
or common cold. Common symptoms and signs of influenza 
infection are listed in Table VII.
In infants and neonates nonspecific signs or fever alone 
may be the only presenting feature. For most children under 2 
years of age, a clinical case definition includes sudden onset of 
high fever, cough and rhinorrhoea during the influenza season.5 
Table VI. Adults with increased risk of complications from 
influenza
•    Cardiorespiratory disorders account for up to 80% of high-
risk conditions potentially complicating influenza during 
epidemics, and the highest rate of complications and greatest 
risk are in persons ≥65 years.
•    Respiratory disorders include chronic obstructive pulmonary 
disease (COPD), asthma and cystic fibrosis.  Although 
asthmatics do not appear to have increased susceptibility 
to viral infections they are likely to develop a more severe 
response to such infections.  Influenza infections occurring 
in patients with chronic lung disease may be associated with 
acute exacerbations of asthma or COPD, greater need for 
hospitalisation, complicating pneumonia, and even death.
•    Cardiac conditions associated with congestive cardiac 
failure are important risk factors for complicated influenza 
infections and carry a particularly high risk of death.
•    Chronic conditions associated with an increased risk of 
complicated infection include:
     •    chronic metabolic conditions such as diabetes mellitus
     •    chronic renal dysfunction
     •    immune deficiency.
•    Residents of chronic care facilities, rehabilitation institutions 
and nursing homes, particularly those with underlying 
chronic medical disorders, are at increased risk of 
complicated infections.  In these situations the infection 
spreads very rapidly once the virus is introduced into the 
population.
•    Pregnant women. It has been documented that influenza 
mortality has occasionally been higher in pregnant women 
during influenza epidemics than in those who are not 
pregnant.
•    HIV-infected individuals. Influenza is more prolonged and 
more severe.
Table II. Indications for influenza vaccine in adults
1.    Persons who are at high risk for influenza and its 
complications because of underlying medical conditions and 
who are receiving regular medical care for conditions such 
as chronic pulmonary and cardiac disease, chronic renal 
diseases, diabetes mellitus and similar metabolic disorders, 
and individuals who are immunosuppressed (including 
HIV-infected persons with CD4 counts above 100 cells/µl)
2.    Residents of old-age homes and chronic care and 
rehabilitation institutions
3.    Medical and nursing staff responsible for the care of high-
risk cases
4.    Adults and children who are family contacts of high-risk 
cases
5.    All persons 65 years of age or older 
6.    Essential services personnel (emergency and security 
personnel), and people who live or work in special 
circumstances (e.g. mine, military, dormitory, large 
workforces, etc.)
7.    Women who would be in the second or third trimester of 
pregnancy during the influenza season.  Pregnant women 
with medical conditions placing them at risk for influenza 
complications should be immunised at any stage of 
pregnancy
8.    Any persons wishing to protect themselves from the risk of 
contracting influenza, especially in industrial settings, where 
large-scale absenteeism could cause significant economic 
losses
Table III. Indications for influenza vaccine in children
1.    All children older than 6 months who are at high risk of 
complications from influenza (see Table VIII), including 
those with chronic pulmonary, cardiac, renal, hepatic, 
endocrine, neurological, metabolic or immunological disease 
that increases the risk of severe influenza
2.    Children on chronic aspirin therapy
3.    Children who are family contacts of young children (under 6 
months of age) or contacts of high-risk people
4.    Some countries recommend routine immunisation of all 
young healthy children from 6 to 59 months of age 
Table IV. Influenza vaccine dosage
Adults: Whole or split-product or subunit vaccine – 1 dose IM
Children (<9 years) or previously vaccinated children:  Split-
product or subunit vaccine – 1 dose IM
Children 3 - 9 years who have never been vaccinated should 
receive 2 doses 1 month apart
Children <3 years of age should receive 0.25 ml on two 
occasions separated 1 month apart when vaccinated for the first 
time
Table V. Contraindications to influenza vaccine
1.    Persons with a history of severe hypersensitivity to eggs
2.    Persons with acute febrile illnesses should preferably be 
immunised after symptoms have disappeared
3.    The vaccine should be avoided in the first trimester of 
pregnancy unless there are specific medical indications – see 
Table II, indication No. 7
Table VII. Common symptoms and signs of influenza 
infection in children
•    Fever
•    Myalgia
•   Malaise
•   Non-productive cough
•   Sore throat
•   Rhinitis
•   Nausea, vomiting
•   Headache
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For older children (>2 years) sudden onset of fever, cough, 
pharyngitis and headache during the influenza season have been 
reported to have a sensitivity and specificity of approximately 
80% each.6 Other symptoms or signs include fatigue (51 - 75%), 
chills (76 - 100%), myalgia or conjunctivitis (26 - 50%). 
The risk of complications from influenza is higher in 
young children than in adults, with approximately 20 - 30% 
of children under 2 years of age developing complications.3,4 
In addition, children with underlying chronic illnesses are at 
increased risk of complications (Table VIII). 
Common complications include febrile convulsions, 
otitis media, sinusitis, bronchiolitis, croup and pneumonia.4  
Pneumonia may be due to viral infection or secondary bacterial 
infection, especially with Streptococcus pneumoniae. The rates 
of hospitalisation and death are increased in children under 
2 years of age and especially in those under 6 months of age. 
Reye’s syndrome, encephalitis, pericarditis and myocarditis are 
rarely reported complications.4  Influenza virus infection may 
exacerbate an underlying chronic illness. 
Influenza is a common (5 - 10%) cause of pneumonia and 
bronchiolitis in children and may be indistinguishable from 
other viral infections (such as respiratory syncytial virus 
(RSV)).6,7 Distinguishing influenza from illness caused by other 
respiratory viruses may be difficult on the basis of signs and 
symptoms, and laboratory diagnostic confirmation may be 
useful.
6. Antiviral agents for influenza 
The antiviral agents currently available for use include the NA 
inhibitors and M1 inhibitors (adamantanes). 
6.1 M1 inhibitors (adamantanes) 
Recent evidence has indicated that a high proportion of the 
circulating influenza A strains in the USA are resistant to 
amantadine (as well as to rimantadine, which is not available 
in South Africa). For this reason more recent editions of the 
Advisory Committee on Immunization Practices (ACIP) 
Recommendations for the Prevention and Control of Influenza have 
indicated that neither amantadine nor rimantadine should 
be used for the treatment or chemoprophylaxis of influenza 
A in the USA.3 Currently, therefore, only NA inhibitors are 
recommended for antiviral treatment or chemoprophylaxis of 
influenza in the USA. 
6.2 NA inhibitors
6.2.1 Treatment of influenza
NA inhibitors are an important adjunct to influenza 
vaccination, in both the prevention and treatment of influenza. 
They act by specifically inhibiting the NA enzymes that are 
present on all influenza subtypes and are responsible for 
releasing viral particles from host cells and the spread of 
infection. Two NA inhibitors are currently available for clinical 
use, oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamivir 
is given orally as a prodrug and is distributed systemically 
to all potential infection sites.  Zanamivir is administered via 
inhalation and is deposited primarily in the respiratory tract. 
When given within 48 hours of onset of symptoms of 
influenza, both agents significantly reduce duration of illness 
and symptom severity, and decrease the rate of influenza-
associated complications, such as pneumonia, bronchitis 
and otitis media.3 The current approved indications for 
oseltamivir are for the treatment of uncomplicated acute 
illness due to influenza infection in patients >1 year of age or 
older, who have been symptomatic for 48 hours or less (but 
British Thoracic Society (BTS) guidelines also recommend that 
oseltamivir can be used up to 5 days into hospitalisation). 
The recommended dose in adults is 1 capsule (75 mg) twice 
daily for 5 days for treatment of influenza and 1 capsule per 
day to a maximum of 6 weeks for prophylaxis. Oseltamivir 
is well tolerated and the most common side-effect has been 
mostly mild nausea or vomiting. Other side-effects are rare and 
include headache, fatigue, insomnia and dizziness. 
Current data indicate that oseltamivir significantly reduces 
the complication rate from influenza in children by up to 
40%, and reduces the need for hospitalisation, the duration 
of hospitalisation in children already hospitalised and the 
duration of illness.8-11  Early diagnosis is essential as treatment 
with oseltamivir should be initiated within the first 48 hours of 
the onset of illness.4,9,10 Oseltamivir is indicated for treatment 
of influenza in children older than 1 year of age to reduce the 
risk of complications and severity of illness. Oseltamivir is 
specifically indicated in children with conditions listed in Table 
IX.10,11 
Dosage of oseltamivir in children
Oseltamivir is available as a capsule (75 mg) or syrup (12 mg/ml). 
The recommended dosage is shown in Table X. 
Zanamivir is similarly approved for the treatment of 
uncomplicated illness due to influenza infection in patients >12 
years of age or older, who have been symptomatic for 48 hours 
Table VIII. Conditions increasing the risk of complications 
from influenza in children
•    Chronic respiratory disease
•    Immunodeficiency (including HIV)
•    Chronic cardiac disease
•    Chronic renal disease
•    Chronic liver disease
•    Diabetes
•    Malignancy
•    Haemoglobinopathy
•    Chronic neurological disease, e.g. diseases with muscle 
weakness
•    On chronic aspirin therapy  
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or less. The recommended dose of zanamivir for the treatment 
of influenza is two inhalations (one 5 mg blister per inhalation 
for a total dose of 10 mg) twice daily.  Zanamivir is generally 
well tolerated, although there have been episodes of decrease 
in lung function and/or bronchospasm in patients with asthma 
and/or underlying airway diseases. Care is needed when 
using zanamivir in patients with underlying airway diseases. 
Individuals with asthma or chronic obstructive pulmonary 
disease (COPD) who are using zanamivir should always have a 
short-acting bronchodilator available when inhaling zanamivir 
and should discontinue therapy and contact their physician if 
they experience difficulty in breathing. 
It has also been recommended that both oseltamivir and 
zanamivir be made part of pandemic influenza preparedness, 
such as for the H5N1 influenza virus (‘bird ‘flu‘). There is 
evidence of ongoing susceptibility of this influenza strain to 
the NA inhibitors. While both may potentially be of benefit, it 
has been suggested that oseltamivir may be particularly useful 
because of its systemic absorption, and the systemic nature of 
H5N1 infection.
Because of concerns about the possibility of resistance 
developing to these agents with overuse, it is recommended 
that their use be reserved for sicker influenza patients or 
for prophylaxis in high-risk patients. They must not replace 
vaccination for prophylaxis (except in the very rare cases where 
vaccine is contraindicated in high-risk patients), but could 
supplement vaccination in high-risk individuals.
Additional treatment for influenza in children
Supportive and symptomatic therapy should be given as 
clinically indicated.4 Oxygen is a mainstay of treatment in 
hypoxic patients. Children or adults with suspected secondary 
bacterial infection or who are severely ill with pneumonia 
requiring hospitalisation should also be treated with an 
antibiotic for community-acquired pneumonia according to 
national guidelines.4,6
6.2.2 Prophylaxis of influenza
Oseltamivir is also effective in adults and adolescents 
(>13 years old), protecting close contacts of index cases 
from symptomatic influenza when used as post-exposure 
prophylaxis. Prophylaxis can be post-exposure (prophylaxis 
for >7 days after exposure to infected individuals), seasonal 
(for the entire influenza season, e.g. in individuals in 
whom vaccination is contraindicated), post-vaccination 
(prophylaxis for 2 - 4 weeks after receiving vaccination) and 
for outbreak control (e.g. institutional outbreak). Prophylaxis is 
recommended for high-risk individuals. 
7. Diagnostic testing
While most cases of influenza are diagnosed clinically, rapid 
tests (Immunocard, Binax Now Influenza A&B, Directigen 
EZ Flu A+B, Denka Seiken Quick Ex-Flu, Fujirebio Espline 
Influenza A&B-N, and Quidel QuickVue Influenza A+B Test) 
are available in South Africa. The sensitivity and specificity 
of locally available testing should be discussed with local 
laboratory experts when requesting these tests. In general, 
rapid tests have a sensitivity of approximately 70%; a negative 
test should therefore be followed by culture. Conventional 
testing of respiratory secretions by immunofluorescence or real-
time polymerase chain reaction (RT-PCR) is offered by most 
laboratories. Cell culture is used for epidemiological purposes. 
The sensitivity of diagnostic assays, especially culture and 
immunofluorescence, differs between age groups and they are 
more sensitive among children, in whom shedding of influenza 
virus is more prolonged (7 - 14 days) than in adults. A negative 
culture/immunofluorescence test does not rule out the 
diagnosis of influenza infection in adults, among whom paired 
serology assays may be more sensitive, but clearly not useful in 
selecting therapy.
8. Influenza and asthma 
Influenza virus continues to be a major cause of respiratory 
infection and is an important contributor to morbidity 
and mortality in populations at risk, including those with 
underlying pulmonary conditions such as asthma. Vaccination 
with inactivated influenza vaccine remains the most popular 
method of controlling influenza through prevention. Patients 
with moderate to severe asthma should be advised to 
receive an influenza vaccination every year, or at least when 
vaccination of the general population is advised. However, 
routine influenza vaccination of children and adults with 
asthma does not appear to protect them from asthma 
exacerbations or improve asthma control.12,13 
9. Influenza and HIV 
Influenza tends to produce more severe disease in HIV-infected 
individuals. The incidence of severe pneumonia in which 
Table IX. Specific indications for oseltamivir in children
•    Life-threatening influenza illness OR
•    High risk for complications of influenza (see Table VIII – high-
risk children should be considered the most important group 
to be considered for treatment with oseltamivir)
•    Oseltamivir has been used in hospitalised children with 
influenza with some success
•    Oseltamivir is not licensed for prophylaxis in children younger 
than 13 years
Table X. Dosage of oral oseltamivir for treatment of 
influenza
Body weight  Dose
<15 kg   30 mg bd
15 - 23 kg   45 mg bd
23 - 40 kg  60 mg bd
>40 kg   75 mg bd
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influenza virus was identified was 8.03-fold (95% confidence 
interval (CI) 5.05 - 12.76) greater in HIV-infected than in HIV-
uninfected children aged <2 years.14 Additionally, whereas 
RSV was the most commonly identified virus (18.1%) in HIV-
uninfected children hospitalised for pneumonia, the frequency 
of identification of influenza virus (5.4%) was the same as 
that for RSV (5.3%) in HIV-infected children hospitalised for 
pneumonia.15 Similar to high-risk HIV-uninfected individuals, 
the mainstay for the prevention of influenza virus infections 
in HIV-infected individuals is immunisation with the trivalent 
sub-unit vaccines. Concerns regarding the use of the sub-unit 
vaccines, which elicit a T-cell-dependent immune response, 
centred around the transient increase in HIV viral load 
and decreases in CD4+ lymphocyte counts observed after 
vaccination in HIV-infected individuals, are considered not to 
be clinically significant in adults or children.14-16 
In summary, vaccination of HIV-infected individuals with 
the sub-unit influenza vaccine is safe; however, it induces only 
moderate immune responses and is modest in the protection 
it confers compared with HIV-uninfected individuals. On the 
basis of the available data, influenza vaccination should be 
considered for adult HIV-infected individuals and has been 
found to be particularly effective in those with CD4 counts 
>100 cells/µl. For children evidence of efficacy is lacking. 
While some guidelines7 suggest that all HIV-infected children 
should receive influenza vaccine, it seems likely that the best 
response will be in those with a CD4 count of >15%. Similarly, 
pneumococcal conjugate vaccine in HIV-infected children 
should be encouraged to prevent superimposed bacterial 
complications of influenza virus infections.
10. Avian influenza
Pandemics caused by highly pathogenic, avian-derived 
influenza A viruses have been documented since the 12th 
century.17,18 The most recent of these was the global disaster of 
1918 - 1919 in which up to 50 - 100 million people died.19 These 
pandemics are related to antigenic shift. The prerequisites 
for the development of a pandemic are that there should 
be a novel virus, that it should be able to cross the species 
barrier causing virulent infection, and finally that there should 
be efficient human-to-human transmission. Fortunately 
most avian strains, even novel viruses such as the H7N7 
strain that recently emerged in Holland, have relatively low 
pathogenicity.20
However, in 1997 in Hong Kong, H5N1, a highly pathogenic 
variety, was identified as a human infection transmitted from 
birds, and at this time a pandemic was probably averted or 
significantly delayed by the destruction of the entire domestic 
bird population in Hong Kong.21 In 2003 antigenic drift 
occurred causing pathogenicity to a larger number of species, 
conferring resistance to amantadine and rimantadine, and 
greatly increasing the virulence. The initial outbreak of human 
disease in 2003 occurred in Vietnam and remained confined to 
south-east Asia until 2005, when the virus was spread by wild 
birds to domestic bird populations in Europe, Africa and the 
Middle East.22 This has significantly increased the numbers of 
people exposed to the virus and commensurately increased the 
potential for mutation to a form that is transmitted between 
humans in an efficient and sustained manner. Cases of human-
to-human transmission have however remained sporadic and 
inefficient.23 As of 5 November  2007, there have been 334 cases 
of H5N1 influenza with 205 deaths in 12 countries (including 
Djibouti, Egypt and Nigeria), a mortality rate of 60%.24  
 Pandemic influenza differs from that of the seasonal variety 
in which death occurs predominantly in the elderly or those 
with co-morbid disease. In 1918 the age-specific mortality 
was highest for those in their teens to 3rd decade.25 In the 205 
human cases that occurred between December 2003 and April 
2006 the mean age was 20 years (range 3 months - 75 years); 
50% were aged under 20 and 90% under 40.26 The overall case 
fatality rate was 56%, with the highest mortality (73%) in the 10 - 
19-year age group (N=49) and the lowest (18%) in those aged over 
50 (N=11).26
Calculation of excess mortality in the 1918 - 1920 pandemic 
from countries that had high-quality registration data shows 
that mortality varied more than 30-fold across countries 
and that per-head income explained most of the variation. 
Extrapolation of these data to 2004 indicates that a similar 
pandemic would kill ±62 million (51 million - 81 million), 
and that 96% (95% CI 95 - 98) of deaths would occur in the 
developing world. If these deaths occurred in a single year, 
they would increase global mortality by 114%.27      
In the event of a pandemic, control by means of case tracing 
and isolation will be impossible as virus is shed prior to the 
development of symptoms.28 Infection control specialists and 
virologists will be valuable primarily to inform clinicians of 
the arrival of H5N1 and that patients should thereafter be 
treated presumptively. The WHO has developed a national 
preparedness plan and has recommended that these be rapidly 
developed, practised and adapted to each specific country.29 
The most important intervention, however, would be an 
effective, widely available and cheaply produced vaccine, 
unfortunately an unlikely scenario in the near future. Antivirals 
would represent the second most important intervention. 
Mathematical modelling of a pandemic similar to 1918, in 
which the mortality was estimated to be 0.5% across all three 
waves, indicated that a stockpile capable of treating 20% 
of the population would result in a mortality reduction of 
53%.30  Excluding the issue of efficacy, the primary problems 
with the use of these NA inhibitors will be early diagnosis of 
the disease, as currently available PCR testing though rapid 
will probably be rendered impractical in the face of massive 
morbidity,31 the logistics of distribution within the 36-hour 
window period, and the potential for the virus to develop 
resistance. 
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All health care workers must be educated with regard to the 
risks of droplet spread of infection to staff and other patients, 
and trained in infection control and disease management. It 
is critically important that all health care workers and others 
involved in essential services are confident that everything 
possible has been done to protect them and their families, 
as fear and demoralisation will compromise their efficiency 
and increase absenteeism. Preparations should be made to 
minimise human-to-human contact, for school, company, 
theatre and cinema closures, and for restriction of mobility 
within the community. Masks must be sourced and plans made 
for distribution. Large employers should develop response 
plans similar to the national recommendations of the WHO.29 
Avian influenza has the potential to cause the biggest health 
care disaster since the 1918 influenza pandemic. Preparation 
should begin now to ameliorate the effects as much as possible.
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